Trial | NCT02194400  Report issue

Title

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    rslv-132 ...

  • Study Participants

    32
A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
Study Started
Jul 31
2014
Primary Completion
Nov 30
2015
Study Completion
Nov 30
2015
Last Update
Dec 09
2015
Estimate

Biological RSLV-132

0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks

Placebo Placebo Comparator

Saline infusion

RSLV-132 Experimental

0.3 - 10 mg/kg experimental drug

Criteria 

Inclusion Criteria:

Stable SLE with no anticipated change in medications for the next 60 days

Exclusion Criteria:

Other biologic drugs
No Results Posted